Oncol Rep 36(2):1166–1172. https://doi.
org/10.3892/or.2016.4874
- Finney Rutten LJ, Nelson DE (2004) Meissner
HI. Examination of population-wide trends in
barriers to cancer screening from a diffusion of
innovation perspective (1987–2000). Prev
Med 38:258–268.https://doi.org/10.1016/
j.ypmed.2003.10.011
- Lo SH, Waller J, Wardle J (2013) Comparing
barriers to colorectal cancer screening with bar-
riers to breast and cervical screening a
population-based survey of screening age
women in great Britain. J Med Screen 20
(2):73–79
- Potter NT, Hurban P, White MN, Whitlock
KD, Lofton-Day CE, Tetzner R, Koenig T,
Quigley NB, Weiss G (2014) Validation of a
real-time PCR-based qualitative assay for the
detection of methylated SEPT9 DNA in
human plasma. Clin Chem 60(9):1183–1191.
https://doi.org/10.1373/clinchem.2013.
221044
- Romero R, Mahoney MJ (2015) Noninvasive
prenatal testing and detection of maternal can-
cer. JAMA 314(2):131–133.https://doi.org/
10.1001/jama.2015.7523
- Bianchi DW, Chudova D, Sehnert AJ (2015)
Noninvasive prenatal testing and incidental
detection of occult maternal malignancies.
JAMA 314(2):162–169.https://doi.org/10.
1001/jama.2015.7120
- Snyder MW, Kircher M, Hill AJ (2016) Cell-
free DNA comprises an in vivo nucleosome
footprint that informs its tissues-of-origin.
Cell 164(1):57–68. https://doi.org/10.
1016/j.cell.2015.11.05.
- Olsson E, Winter C, George A, Chen Y,
Howlin J, Tang MH, Dahlgren M, Schulz R,
Grabau D, van Westen D, Ferno ̈M, Ingvar C,
Rose C, Bendahl PO, Ryde ́n L, Borg A ̊,
Gruvberger-Saal SK, Jernstro ̈m H, Saal LH
(2015) Serial monitoring of circulating tumour
DNA in patients with primary breast cancer for
detection of occult metastatic disease. EMBO
Mol Med 7(8):1034–1047.https://doi.org/
10.15252/emmm.201404913
- Reinert T, Schøler LV, Thomsen R,
Tobiasen H, Vang S, Nordentoft I, Lamy P,
Kannerup AS, Mortensen FV, Stribolt K,
Hamilton-Dutoit S, Nielsen HJ, Laurberg S,
Pallisgaard N, Pedersen JS, Ørntoft TF, Ander-
sen CL (2016) Analysis of circulating tumour
DNA to monitor disease burden following
colorectal cancer surgery. Gut 65:gutjnl-2014.
https://doi.org/10.1136/gutjnl-2014-
308859
- Tie J, Kinde I, Wang Y (2014) Circulating
tumour DNA (ctDNA) as a marker of
recurrence risk in stage II colon cancer (CC).
ASCO annual meeting proceedings, Chicago
- Quasar Collaborative Group, Gray R,
Barnwell J, McConkey C, Hills RK, Williams
NS, Kerr DJ (2007) Adjuvant chemotherapy
versus observation in patients with colorectal
cancer: a randomised study. Lancet
370:2020–2029. https://doi.org/10.1016/
S0140-6736(07)61866-2
43.www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm504488.htm.
- Kuang Y, Rogers A, Yeap BY, Wang L,
Makrigiorgos M, Vetrand K, Thiede S, Distel
RJ, J€anne PA (2009) Noninvasive detection of
EGFR T790M in gefitinib or erlotinib resistant
non–small cell lung cancer. Clin Cancer Res 15
(8):2630–2636. https://doi.org/10.1158/
1078-0432.CCR-08-2592
- Nakamura T, Sueoka-Aragane N, Iwanaga K,
Sato A, Komiya K, Kobayashi N, Hayashi S,
Hosomi T, Hirai M, Sueoka E, Kimura S
(2012) Application of a highly sensitive detec-
tion system for epidermal growth factor recep-
tor mutations in plasma DNA. J Thorac Oncol
7(9):1369–1381. https://doi.org/10.1097/
JTO.0b013e31825f2821
- Kimura H, Kasahara K, Kawaishi M,
Kunitoh H, Tamura T, Holloway B, Nishio K
(2006) Detection of epidermal growth factor
receptor mutations in serum as a predictor of
the response to gefitinib in patients with non–-
small-cell lung cancer. Clin Cancer Res 12
(13):3915–3921. https://doi.org/10.1158/
1078-0432.CCR-05-2324
- Luo J, Shen L, Zheng D (2014) Diagnostic
value of circulating free DNA for the detection
of EGFR mutation status in NSCLC: a system-
atic review and meta-analysis. Sci Rep 4:6269.
https://doi.org/10.1038/srep06269
- Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F,
Xu L, Yin R (2014) Circulating tumour DNA
is effective for the detection of EGFR mutation
in non–small cell lung cancer: a meta-analysis.
Cancer Epidemiol Prev Biomarkers 24
(1):206–212. https://doi.org/10.1158/
1055-9965.EPI-14-0895
- Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V,
Sandoval-Tan J, Ladrera G, Thongprasert S,
Srimuninnimit V, Liao M, Zhu Y, Zhou C,
Fuerte F, Margono B, Wen W, Tsai J,
Truman M, Klughammer B, Shames DS, Wu
L (2015) Detection and dynamic changes of
EGFR mutations from circulating tumour
DNA as a predictor of survival outcomes in
NSCLC patients treated with first-line interca-
lated erlotinib and chemotherapy. Clin Cancer
Res 21(14):3196–3203.https://doi.org/10.
1158/1078-0432.CCR-14-2594
The Introduction and Clinical Application of Cell-Free Tumor DNA 63
